Explore 3 Stock Ideas & Industry Insights Download Free Report

National Research Corp

Healthcare US NRC

19.75USD
0.71(3.73%)

Last update at 2026-06-04T20:00:00Z

Day Range

19.3419.99
LowHigh

52 Week Range

28.5146.84
LowHigh

Fundamentals

  • Previous Close 19.04
  • Market Cap719.18M
  • Volume134786
  • P/E Ratio24.49
  • Dividend Yield1.58%
  • EBITDA45.78M
  • Revenue TTM147.42M
  • Revenue Per Share TTM6.05
  • Gross Profit TTM 94.52M
  • Diluted EPS TTM1.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 42.81M 48.62M 41.47M 40.52M 34.71M
Minority interest - - - - -
Net income 31.80M 37.47M 37.26M 32.41M 30.05M
Selling general administrative 42.70M 38.96M 34.44M 32.97M 31.37M
Selling and marketing expenses - - - - -
Gross profit 94.52M 95.60M 84.09M 81.55M 72.11M
Reconciled depreciation 5.28M 6.37M 7.50M 5.54M 5.46M
Ebit 46.54M 50.27M 42.68M 43.03M 36.22M
Ebitda 51.87M 56.66M 50.25M 48.15M 41.69M
Depreciation and amortization 5.33M 6.39M 7.58M 5.11M 5.46M
Non operating income net other -2.51900M 0.02M 0.60M -0.42500M 0.95M
Operating income 46.54M 50.27M 42.68M 43.03M 35.27M
Other operating expenses 105.03M 97.68M 91.13M 84.95M 84.41M
Interest expense 1.21M 1.67M 1.81M 2.09M 1.51M
Tax provision 11.02M 11.15M 4.21M 8.11M 4.66M
Interest income 0.17M 0.01M 0.02M 0.04M 0.06M
Net interest income -1.04100M -1.65300M -1.79500M -2.05400M -1.45100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 11.02M 11.15M 4.21M 8.11M 4.66M
Total revenue 151.57M 147.95M 133.28M 127.98M 119.69M
Total operating expenses 47.98M 45.33M 41.95M 38.51M 36.83M
Cost of revenue 57.05M 52.35M 49.19M 46.44M 47.58M
Total other income expense net -3.72800M -1.64900M -1.21000M -2.51600M 0.89M
Discontinued operations - - - - -
Net income from continuing ops 31.80M 37.47M 37.26M 32.41M 30.05M
Net income applicable to common shares 31.80M 37.47M 37.26M 32.41M 30.05M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 122.44M 130.46M 157.54M 133.42M 110.69M
Intangible assets 1.47M 1.61M 1.79M 1.41M 1.73M
Earning assets - - - - -
Other current assets 5.08M 4.23M 4.87M 4.26M 3.93M
Total liab 73.48M 58.43M 72.20M 69.11M 77.79M
Total stockholder equity 48.95M 72.03M 85.34M 64.31M 32.89M
Deferred long term liab - 5.27M 3.77M 4.55M 4.20M
Other current liab 12.25M 8.59M 11.50M 10.94M 12.22M
Common stock 0.03M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.03M
Retained earnings -30.53000M -25.18400M -36.11200M -61.37500M -93.35700M
Other liab - 6.95M 9.55M 10.88M 8.14M
Good will 61.61M 61.61M 61.61M 57.26M 57.94M
Other assets - 5.72M 9.83M 8.92M 5.41M
Cash 6.65M 25.03M 54.36M 34.69M 13.52M
Cash and equivalents - - - - -
Total current liabilities 36.20M 33.42M 40.39M 31.68M 38.16M
Current deferred revenue 14.83M 15.20M 17.21M 15.59M 16.65M
Net debt 32.30M -2.84500M -27.81400M -4.08200M 20.66M
Short term debt 7.82M 4.49M 4.28M 4.06M 4.38M
Short long term debt 7.21M 4.49M 4.28M 4.06M 4.38M
Short long term debt total 38.96M 22.18M 26.55M 30.61M 34.17M
Other stockholder equity 79.45M 97.19M 123.79M 128.06M 128.43M
Property plant equipment - 17.25M 12.39M 11.73M 13.53M
Total current assets 24.36M 43.72M 73.71M 54.11M 29.16M
Long term investments - - - - 1.30M
Net tangible assets - 8.81M 23.72M 64.31M 32.89M
Short term investments - - - - -
Net receivables 12.62M 14.46M 14.48M 15.16M 11.71M
Long term debt 29.47M 17.69M 22.27M 26.55M 29.80M
Inventory - - - - -
Accounts payable 1.30M 5.14M 7.39M 1.09M 4.91M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - -2.37500M -2.39900M -2.20900M
Additional paid in capital - - - - -
Common stock total equity - 0.03M 0.03M 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -25.18400M -36.11200M -61.37500M -93.35700M
Treasury stock - -78.26700M -50.14900M -43.72700M -33.72600M
Accumulated amortization - - - - -
Non currrent assets other 4.73M 7.87M 9.83M 10.33M 10.06M
Deferred long term asset charges - - - - -
Non current assets total 98.08M 86.75M 83.83M 79.31M 81.53M
Capital lease obligations - - - - -
Long term debt total - 17.69M 22.27M - 30.35M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -13.97400M -9.83500M -8.51400M -3.72400M -4.65600M
Change to liabilities - -3.53000M 0.20M -0.40600M 1.46M
Total cashflows from investing activities - -9.83500M -8.51400M -3.72400M -4.65600M
Net borrowings - -4.39700M -4.09300M -3.60400M -3.71500M
Total cash from financing activities -40.70700M -55.58300M -18.16200M -15.50300M -36.34600M
Change to operating activities - -0.02100M -0.37800M 0.21M -0.45000M
Net income 30.96M 31.80M 37.47M 37.26M 32.41M
Change in cash -18.37300M -29.33500M 19.67M 21.17M 0.53M
Begin period cash flow 25.03M 54.36M 34.69M 13.52M 12.99M
End period cash flow 6.65M 25.03M 54.36M 34.69M 13.52M
Total cash from operating activities 38.11M 36.27M 46.34M 40.64M 40.92M
Issuance of capital stock - - - - -
Depreciation 5.90M 5.28M 6.37M 7.50M 5.54M
Other cashflows from investing activities - - -3.00000M 0.26M 0.26M
Dividends paid 36.37M 20.96M 9.16M 10.52M 31.30M
Change to inventory -0.00000M - -1.12700M 0.54M 0.28M
Change to account receivables 2.08M -0.73300M 0.34M -2.27100M 0.31M
Sale purchase of stock -19.09900M -27.61600M -4.14200M 1.73M -1.10300M
Other cashflows from financing activities 28.65M -2.23200M -0.72100M -1.08600M 19.90M
Change to netincome - -0.03000M 0.66M 0.74M 2.36M
Capital expenditures 15.78M 9.84M 5.51M 3.98M 4.66M
Change receivables - -0.73300M 0.34M -2.27100M 0.31M
Cash flows other operating - 3.48M 1.29M -2.19500M -1.15900M
Exchange rate changes - - 0.00300M -0.23600M 0.61M
Cash and cash equivalents changes - -29.15300M 19.67M 21.17M 0.53M
Change in working capital 1.02M -3.35100M 1.84M -4.61200M 0.62M
Stock based compensation 0.94M 1.20M 0.62M 0.68M 1.22M
Other non cash items 0.00800M 3.07M 0.00700M -0.24800M -0.00600M
Free cash flow 22.33M 26.43M 40.83M 36.65M 36.26M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NRC
National Research Corp
0.71 3.73% 19.75 24.49 - 5.48 16.62 5.68 18.05
VEEV
Veeva Systems Inc Class A
-0.12 0.07% 178.60 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc
- -% 8.55 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc
0.08 1.70% 4.79 31.84 26.25 0.05 4.60 0.04 0.12
BTSG
BrightSpring Health Services, Inc. Common Stock
-3.48 5.72% 57.40 100.22 40.65 0.69 4.92 0.92 25.80

Reports Covered

Stock Research & News

Profile

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

National Research Corp

1245 Q Street, Lincoln, NE, United States, 68508

Key Executives

Name Title Year Born
Mr. Michael D. Hays Founder, CEO, Pres & Director 1955
Mr. Kevin R. Karas CPA, CPA Sr. VP of Fin., CFO, Treasurer & Sec. 1958
Ms. Jona S. Raasch Chief Operating Officer 1959
Ms. Helen L. Hrdy Chief Growth Officer 1965
Mr. Jon Boumstein Chief Delivery Officer NA
Dr. Gregory Makoul M.S., Ph.D. Chief Transformation Officer NA
Linda Stacy VP of Fin. NA
Megan Charko Sr. Mang. of Content Marketing NA
Mr. Michael D. Hays Founder, CEO, President & Director 1955
Ms. Helen L. Hrdy Chief Customer Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions